Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2004

View Archived Issues

Corpus cavernosum relaxation induced by a Ferulago syriaca root extract

Tacrolimus reported more effective than hydrocortisone acetate in atopic dermatitis

New phosphatase inhibitors active against hepatoma cells in vitro

Small molecule inhibitor of hypoxia-inducible factor-1 identified

Novel androgen receptor antagonist for advanced prostate cancer therapy designed by BMS

Approval for new dosage of Zantac EFFERdose

BCY LifeSciences in discussions with potential partners for DCF-987

Evotec enters screening and medicinal chemistry collaboration with Fujisawa

GlaxoSmithKline to acquire Fraxiparine and Arixtra

Novacea provides evidence for the antitumor effects of DN-101 and AQ4N

Chugai highlights FY 2003 developments

A preliminary study suggests gabapentin may be effective for recurrent idiopathic priapism

Eisai describes novel, potent orally active small molecule thrombin receptor antagonists

CB-300945, a novel selective alpha-FR targeted thymidylate synthase inhibitor

Novel NMDA antagonists selective for the NR2B subtype described by Merck

Lupin patent covers an anticonvulsant plant extract

Six related series of PDE4 inhibitors reported by Altana Pharma

New prostanoid EP4 agonists for glaucoma therapy claimed by Merck Frosst

Merck team designs novel bradykinin B1 antagonists for pain and inflammation

Novel p38 MAP kinase inhibitors under study at Pfizer

New muscarinic receptor antagonists prepared and tested at Ranbaxy

Aldara receives approvable letter for superficial BCC

Positive interim reports on cognitive function in Alzhemed trial

New phase I trial for VEGF Trap

Early completion of enrollment in pivotal Actimmune trial for ovarian cancer

BlockAide/CR cleared to enter phase Ib/IIa trial

Nasacort HFA nasal aerosol receives FDA approval

Positive results for phase II trial of ThGRF for HIV-related lipodystrophy

Gloucester Pharmaceuticals acquires license to FK-228

LAB International partners with Ferrer for Fentanyl TAIFUN

NDA filing for Surfaxin for RDS in premature infants